24 July 2012

Home / July 24, 2012

New drug combination offers hope in fight against tuberculosis

A new combination of drugs to treat tuberculosis (TB) could offer renewed hope in the fight against the disease, thought to kill around 1.4 million people every year. The results of a Phase II trial involving 85 patients, and reported in The Lancet, show that the new combination could kill more than 99% of patients'€™ TB bacteria within two weeks, and could lead to improved treatment for patients infected with forms of TB that are resistant to existing drug treatments, as well as those infected with drug-susceptible TB.
Read More » New drug combination offers hope in fight against tuberculosis

Trial signals major milestone in hunt for new TB drugs

WASHINGTON'€” A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet. These results add to a growing body of evidence that the new regimen could reduce treatment by more than a year for some patients.
Read More » Trial signals major milestone in hunt for new TB drugs

HIV/AIDS: Better paediatric HIV formulations

WASHINGTON DC, 23 July 2012 (PLUSNEWS) - Fewer babies are being born HIV-positive, but treatment for the more than three million children living with HIV remains under-researched and underfunded. As part of efforts to boost access to paediatric HIV treatment, researchers are getting creative, moving to better pills, kid-friendly treatment "sprinkles", micro-tabs and even medicine-dispensing pacifiers.
Read More » HIV/AIDS: Better paediatric HIV formulations

Newsletter Subscription

Enable Notifications OK No thanks